Demonstrates luteolin's ability to alleviate granulosa cell pyroptosis in PCOS, suggesting its therapeutic potential for inflammatory reproductive disorders.
Key Points
The study aims to investigate the effects of luteolin on granulosa cell pyroptosis in the context of polycystic ovary syndrome (PCOS).
Developed a DHEA-induced PCOS rat model to assess luteolin's effects.
Measured hormone and cytokine levels using ELISA.
Conducted in vitro studies with DHT-treated KGN cells for granulosa cell dysfunction.
Assessed pyroptosis using CCK-8, LDH release, and electron microscopy.
Analyzed expression of AR, STAT3, and NLRP3 using Western blot and immunohistochemistry.
Luteolin treatment improved hormonal balance and ovarian morphology in PCOS rats.
Luteolin suppressed STAT3 phosphorylation and NLRP3 activation in both in vivo and in vitro.
Network pharmacology identified STAT3 as a primary target of luteolin with a binding energy of -8.589 kcal/mol.